Loading…
Orchid Lifesciences, an OTC drug manufacturer in India, failed to meet Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, resulting in adulterated drug products including toothpaste and topical analgesics. The company did not conduct required identity testing on incoming components at high risk of contamination, specifically failing to adequately test glycerin, propylene glycol, and sorbitol solution for diethylene glycol (DEG) or ethylene glycol (EG) contamination in violation of 21 CFR 211.84(d)(1). This warning followed an FDA inspection and the company's response to a January 25, 2023 records request under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act.